Earlier this month, the Chinese government announced it was setting up a body to regulate the stem cell therapy sector, to stop unlicensed bodies setting up to cash in on what is a major growth market.
However, the regulations are still in an early form, and Beike is strongly supported by local government agencies, and is unlikely to fall foul of new rules.
Stories of patients travelling to China for costly stem cell therapies depress Dr Stephen Sullivan, visiting research fellow at Trinity College Dublin.
“It’s not because of the loss of money, but rather that stem cell research has yet to give patients and their loved ones a legitimate option,” he says.
Read it all.
China fails to convince on stem cell claims
Earlier this month, the Chinese government announced it was setting up a body to regulate the stem cell therapy sector, to stop unlicensed bodies setting up to cash in on what is a major growth market.
However, the regulations are still in an early form, and Beike is strongly supported by local government agencies, and is unlikely to fall foul of new rules.
Stories of patients travelling to China for costly stem cell therapies depress Dr Stephen Sullivan, visiting research fellow at Trinity College Dublin.
“It’s not because of the loss of money, but rather that stem cell research has yet to give patients and their loved ones a legitimate option,” he says.
Read it all.